Results 111 to 120 of about 116,934 (269)

Exploring the functional domain and the target of the tetanus toxin light chain in neurohypophysial terminals [PDF]

open access: yes, 1994
The tetanus toxin light chain blocks calcium induced vasopressin release from neurohypophysial nerve terminals. Here we show that histidine residue 233 within the putative zinc binding motif of the tetanus toxin light chain is essential for the ...
Weller, U.   +7 more
core   +1 more source

Therapeutic Uses and Efficacy of Botulinum Toxin in Orofacial Medicine: A Dental Perspective

open access: yesToxins
Botulinum neurotoxin (BoNT) is the exotoxin of Clostridium botulinum, a Gram-positive, spore-forming bacterium [...]
Kazuya Yoshida, Merete Bakke
doaj   +1 more source

Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance

open access: yesFrontiers in Bioengineering and Biotechnology, 2018
Botulism outbreak due to consumption of food contaminated with botulinum neurotoxins (BoNTs) is a public health emergency. The threat of bioterrorism through deliberate distribution in food sources and/or aerosolization of BoNTs raises global public ...
Nagarajan Thirunavukkarasu   +13 more
semanticscholar   +1 more source

Targeted liquid chromatography–tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary People with chronic migraine may have changes in amino‐acid metabolism, but it remains unclear which metabolic pathways are associated with the disease and early response to onabotulinumtoxinA treatment. We measured plasma amino‐acid levels in patients with chronic migraine and healthy controls and assessed changes after 1 month ...
Seyma Dumur   +6 more
wiley   +1 more source

An Ultrasensitive Gold Nanoparticle-based Lateral Flow Test for the Detection of Active Botulinum Neurotoxin Type A

open access: yesNanoscale Research Letters, 2017
Botulism is a severe and potentially lethal paralytic disease caused by several botulinum neurotoxin-producing Clostridia spp. In China, the majority of the cases caused by botulism were from less-developed rural areas.
Jing Liu   +10 more
doaj   +1 more source

Positional Relationship Between the Orbicularis Oculi and Zygomaticus Complex Muscles by Ultrasonography: New Anatomical Insights for Crow's Feet Injection

open access: yesClinical Anatomy, Volume 39, Issue 6, Page 662-671, September 2026.
ABSTRACT The orbicularis oculi muscle (OOc) is strongly associated with facial aging as its contraction causes the formation of crow's feet. Botulinum neurotoxin (BoNT) injection is a representative treatment targeting muscle. The aim of this study was to demonstrate the anatomical relationship between the OOc and the zygomaticus complex muscles, and ...
Jiong‐Zhen Piao   +3 more
wiley   +1 more source

Botulinum Neurotoxin-Producing Bacteria. Isn’t It Time that We Called a Species a Species?

open access: yesmBio, 2018
Botulinum neurotoxins (BoNTs) are produced by a diverse set of seven clostridial species, though alternate naming systems have developed over the last 100 years. Starting in the 1950s, a single-species taxonomy where any bacterium producing BoNT would be
Theresa J. Smith   +4 more
semanticscholar   +1 more source

A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19‐Year‐Old Female With Schizophrenia

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT A 19‐year‐old female with schizophrenia developed severe mixed tardive syndrome (choreoathetoid dyskinesia with prominent tardive dystonia) after antipsychotic treatment, which remained debilitating despite deutetrabenazine, benzodiazepines, baclofen, and amantadine.
Wen‐mao Yang   +5 more
wiley   +1 more source

What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection

open access: yes, 2009
PURPOSE: We documented the effects of intradetrusor injections of botulinum neurotoxin type A (Botox(R)) for refractory idiopathic detrusor overactivity so that prospective patients maybe properly informed about possible improvement in quality of life ...
Panicker, Jalesh   +10 more
core   +1 more source

Emerging Opportunities for Serotypes of Botulinum Neurotoxins

open access: yesToxins, 2012
Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity.
John Tapia-Núñez   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy